on the 2nd poster: 1080-05 Epigenetic Reader Inhibitor Apabetalone....

The final conclusion: "Findings support the development of apabetalone as a therapy for high risk CVD patients with epigenetic dysregulation of the innate immune response"

...note: the conclusion goes beyond recommending apabetalone for development for only those with DM2.  To me this is sginificant, but it would also require more trials and more money